Peflacine (Tablet)

Pefloxacin 400 mg Sanofi Bangladesh Limited Unit Price: ৳ 15.28 (30’s pack: ৳ 458.4) Indications Pefloxacin is indicated for the treatment of single or mixed infections caused by two or more susceptible organisms. It can also be used for infections caused by organisms resistant to other antibiotics including aminoglycoside, penicillin and cephalosporin. Pefloxacin is indicated

Menactra (SC Injection)

Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 ml/vial Sanofi Bangladesh Limited 0.5 ml vial: ৳ 3,803.94 Indications Polysaccharide Diphtheria Toxoid Conjugate Vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. This vaccine is approved for use in individuals 9 months through 55 years of

Macrocin-T (Lotion)

Erythromycin 2% Sanofi Bangladesh Limited 30 ml bottle: ৳ 200.61 Indications For topical treatment of acne, pimples & bacterial skin infections susceptible to Erythromycin Therapeutic Class Topical antibiotics for Acne Pharmacology Erythromycin is a bacteriostatic macrolide antibiotic, but may be bactericidal in high concentrations. Although the mechanism by which topical erythromycin acts in reducing inflammatory

Pretor (Capsule)

Pregabalin 50 mg Sanofi Bangladesh Limited Unit Price: ৳ 12.04 (30’s pack: ৳ 361.2) Also available as: 75 mg (Capsule) Indications Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy and management of post-herpetic neuralgia. It is also indicated for the adjunctive therapy for adult patients with partial onset seizures. It

Fiprox (Tablet)

Ciprofloxacin 500 mg Sanofi Bangladesh Limited Unit Price: ৳ 14.09 (30’s pack: ৳ 422.7) Also available as: 250 mg (Tablet) 750 mg (Tablet) × Prescribing Monograph for Ciprofloxacin Tablet & Oral Suspension Injection Indications Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient

Enocef (IM Injection)

Ceftriaxone 500 mg/vial Sanofi Bangladesh Limited 500 mg vial: ৳ 150.57 Also available as: 1 gm/vial (Injection) 250 mg/vial (Injection) Indications Ceftriaxone is indicated for the treatment of sepsis, meningitis, abdominal infections (peritonitis, infections of the biliary and gastro intestinal tracts), infections of the bones, joints, soft tissue, skin and/or wounds infections in patients with

Motilon (Injection)

Metoclopramide Hydrochloride 10 mg/2 ml Sanofi Bangladesh Limited 2 ml ampoule: ৳ 3.77 (10’s pack: ৳ 37.7) Indications Intubation of the small intestine, Premedication for radiologic examination of the upper gastrointestinal tract, Prophylaxis of chemotherapy-induced nausea and vomiting, Nausea and vomiting associated with cancer chemotherapy or radiotherapy, Diabetic gastric stasis, Gastro-oesophageal reflux disease, Diabetic gastric stasis, Prophylaxis of postoperative nausea

Fiprox (Tablet)

Ciprofloxacin 250 mg Sanofi Bangladesh Limited Unit Price: ৳ 8.53 (30’s pack: ৳ 255.9) Also available as: 500 mg (Tablet) 750 mg (Tablet) × Prescribing Monograph for Ciprofloxacin Tablet & Oral Suspension Injection Indications Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient

Imojev (SC Injection)

Encephalitis Vaccine 0.5 ml/vial Sanofi Bangladesh Limited 0.5 ml vial: ৳ 2,040.28 Indications Encephalitis vaccine is indicated for prophylaxis of Japanese encephalitis caused by the Japanese encephalitis virus, in persons from 9 months of age and over. Therapeutic Class Vaccines, Anti-sera & Immunoglobulin Pharmacology The vaccine is a live attenuated virus. Following administration, the virus

Fludara (Tablet)

Fludarabine Phosphate 10 mg Sanofi Bangladesh Limited Unit Price: ৳ 950.00 (20’s pack: ৳ 19000) × Prescribing Monograph for Fludarabine Phosphate Tablets Injection Indications Fludarabine Phosphate is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard